Zoetis (ZTS) Operating Income (2012 - 2026)
Zoetis' (ZTS) quarterly Operating Income came in at $833.0 million in Q1 2026, down 1.3% year-on-year from $844.0 million in Q1 2025, and down 0.95% on a QoQ basis from $841.0 million in Q4 2025.
Zoetis (ZTS) Operating Income (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Operating Income data on file, last reported at $833.0 million in Q1 2026.
- On a quarterly basis, Operating Income fell 1.3% year-over-year to $833.0 million in Q1 2026; TTM through Mar 2026 was $3.6 billion, a 4.01% increase from a year earlier, with the FY2025 full-year figure at $3.7 billion, up 5.63% from the prior year.
- Operating Income for Q1 2026 stood at $833.0 million, down from $841.0 million in the prior quarter.
- Over the last five years, Operating Income for ZTS reached as high as $992.0 million in Q2 2025 and fell as low as $728.0 million in Q4 2022.
- Historically, Operating Income has averaged $834.8 million across 5 years, with a median of $833.0 million in 2026.
- Across the five-year window, Operating Income soared 62.67% in 2022 and declined 10.14% in 2023, its largest moves.
- Year by year, Operating Income stood at $728.0 million in 2022, then gained by 1.37% to $738.0 million in 2023, then advanced by 7.99% to $797.0 million in 2024, then gained by 5.52% to $841.0 million in 2025, then retreated by 0.95% to $833.0 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were $833.0 million in Q1 2026, $841.0 million in Q4 2025, and $964.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 325.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 833.00 Mn |
| Dec 31, 2025 | 841.00 Mn |
| Sep 30, 2025 | 964.00 Mn |
| Jun 30, 2025 | 992.00 Mn |
| Mar 31, 2025 | 844.00 Mn |
| Dec 31, 2024 | 797.00 Mn |
| Sep 30, 2024 | 950.00 Mn |
| Jun 30, 2024 | 899.00 Mn |
| Mar 31, 2024 | 834.00 Mn |
| Dec 31, 2023 | 738.00 Mn |
| Sep 30, 2023 | 820.00 Mn |
| Jun 30, 2023 | 863.00 Mn |
| Mar 31, 2023 | 744.00 Mn |
| Dec 31, 2022 | 728.00 Mn |
| Sep 30, 2022 | 754.00 Mn |
| Jun 30, 2022 | 762.00 Mn |
| Mar 31, 2022 | 828.00 Mn |
| Dec 31, 2021 | 632.00 Mn |
| Sep 30, 2021 | 759.00 Mn |
| Jun 30, 2021 | 744.00 Mn |